Abstract:Dear Editor, We read with great interest the article entitled The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis by Alavian et al. [1]. published in Hepatitis Monthly. In this article, the authors performed an elegant meta-analysis of randomized controlled trials to compare the different effects (including efficacy and safety) of using two types of peginterferon, alpha-2a (PEG-IFN-α2a) and 2b (PEG-IFN-α2b) in the treatment of chronic hepatitis C virus (HCV) infection. By pooling data from 7 randomized controlled trials, the authors concluded that PEG-IFN-α2a with similar safety is more effective than PEG-IFN-α2b; and that a longer duration of maximum serum concentration compared with PEG-IFN-α2b yields a greater sustained virological response and higher neutropenia in PEG-IFN-α 2a recipients. These analysis results are of important clinical directive significance for using interferon alpha (IFN-α) to treat HCV-related liver diseases. HCV and HBV infections are major global causes of liver-related morbidity and mortality; and they are also the most common etiologies of hepatocellular carcinoma (HCC). However, IFN-α not only has antiviral activities with clearance or suppression of HBV and HCV, but also possesses anti-tumor properties including antiproliferative, antiangiogenic, and immunomodulatory effects [2][3][4]. In recent years, we and others have also done some excellent research work on this issue. In 2006 [5], we performed an immunohistochemical study of P48 staining on specimens that were collected from patients, in a randomized trial, who received postoperative IFN-a therapy (80 patients) and who did not receive postoperative IFN-a therapy (75 patients); study results indicated that P48 was useful as a predictive marker of outcome after postoperative IFN-a treatment in patients with HBV-related HCC. Owing to the fact that the included subpopulation in our study consisted mostly of HBV-positive patients, whether our study results were suitable for HCV-positive patients is still unknown; so our further research may focus on this subpopulation. To the best of our knowledge, IFN-α has been widely used in the prevention and treatment of HCV or HBV- related liver diseases (including hepatitis, cirrhosis, HCC etc.) both in western and Asian countries; it alone or in combination with other agents might offer a good therapeutic option for patients with HCV or HBV-related liver diseases. Further explorations of the benefits of this use would be worthwhile.

Inhibition of HBV Gene Expression and Replication by Stably Expressed Interferon‐α1 Via Adeno‐associated Viral Vectors

The Anti-Hbv Effect Mediated by a Novel Recombinant Eukaryotic Expression Vector for IFN-α

Transfer and Expression of Human Interferon- Α Gene and Its Effect on HBV Inhibition

Interferon-α modulates HBV specific T-cell response to inhibit viral gene expression in chronic HBV infection mouse model

Inhibition of HBV Replication and Gene Expression in Vitro and in Vivo with a Single AAV Vector Delivering Two Shrna Molecules.

Susceptibility of Different Hepatitis B Virus Isolates to Interferon-Alpha in a Mouse Model Based on Hydrodynamic Injection.

Study on the Anti- HBV Effects of Transgenically Expressed IFN-α1

Adeno-Associated Virus Vector-Mediated Sirna Inhibition Of Hepatitis B Virus Gene Expression In Vitro

A Potential Functional Cure In Chinese Hbeag-Negative Chronic Hepatitis B Patients Treated With Peg-Interferon Alpha-2a

Inhibition of Hepatitis B Virus by Small Interfering RNA Expressed from Adenovirus-associated Virus Vectors

Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line

Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy

TREATMENT WITH PEGYLATED INTERFERON-ALPHA INDUCES SUSTAINED SUPPRESSION OF BOTH VIRUS REPLICATION AND ANTIGENEMIA IN HUMANIZED Upa/scid MICE STABLY INFECTED WITH HBV

Antiviral Activity of Interferon Alpha-Inducible Protein 27 Against Hepatitis B Virus Gene Expression and Replication

Effective Inhibition of Hepatitis B Virus Replication by Small Interfering RNAs Expressed from Human Foamy Virus Vectors.

Different Antiviral Effects of IFNα and IFNβ in an HBV Mouse Model.

Interferon and interferon-stimulated genes in HBV treatment

Interferon Alpha Induces Cellular Autophagy and Modulates Hepatitis B Virus Replication

Tolerability, Pharmacokinetics and Antiviral Activity of Rhsa/ifnα2a for the Treatment of Chronic Hepatitis B Infection.

Inhibition of STAT1 Methylation is Involved in the Resistance of Hepatitis B Virus to Interferon Alpha

Interferon: a Sharp Sword to Overcome HCV or HBV-related Liver Diseases?